Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 2
2003 3
2004 2
2005 2
2013 3
2014 2
2015 2
2018 1
2019 1
2020 2
2021 9
2022 10
Text availability
Article attribute
Article type
Publication date

Search Results

36 results
Results by year
Filters applied: . Clear all
Page 1
Comparative effectiveness of guselkumab in psoriatic arthritis: results from systematic literature review and network meta-analysis.
Mease PJ, McInnes IB, Tam LS, Eaton K, Peterson S, Schubert A, Chakravarty SD, Parackal A, Karyekar CS, Nair S, Boehncke WH, Ritchlin C. Mease PJ, et al. Among authors: karyekar cs. Rheumatology (Oxford). 2021 May 14;60(5):2109-2121. doi: 10.1093/rheumatology/keab119. Rheumatology (Oxford). 2021. PMID: 33844022 Free PMC article.
Resolution of enthesitis by guselkumab and relationships to disease burden: 1-year results of two phase 3 psoriatic arthritis studies.
McGonagle D, McInnes IB, Deodhar A, Schett G, Shawi M, Kafka S, Karyekar CS, Kollmeier AP, Hsia EC, Xu XL, Sheng S, Agarwal P, Zhou B, Ritchlin CT, Rahman P, Mease PJ. McGonagle D, et al. Among authors: karyekar cs. Rheumatology (Oxford). 2021 Nov 3;60(11):5337-5350. doi: 10.1093/rheumatology/keab285. Rheumatology (Oxford). 2021. PMID: 33822898 Free PMC article. Clinical Trial.
Guselkumab demonstrated an independent treatment effect in reducing fatigue after adjustment for clinical response-results from two phase 3 clinical trials of 1120 patients with active psoriatic arthritis.
Rahman P, Mease PJ, Helliwell PS, Deodhar A, Gossec L, Kavanaugh A, Kollmeier AP, Hsia EC, Zhou B, Lin X, Shawi M, Karyekar CS, Han C. Rahman P, et al. Among authors: karyekar cs. Arthritis Res Ther. 2021 Jul 14;23(1):190. doi: 10.1186/s13075-021-02554-3. Arthritis Res Ther. 2021. PMID: 34261541 Free PMC article. Clinical Trial.
Guselkumab, an inhibitor of the IL-23p19 subunit, provides sustained improvement in signs and symptoms of active psoriatic arthritis: 1 year results of a phase III randomised study of patients who were biologic-naïve or TNFα inhibitor-experienced.
Ritchlin CT, Helliwell PS, Boehncke WH, Soriano ER, Hsia EC, Kollmeier AP, Chakravarty SD, Zazzetti F, Subramanian RA, Xu XL, Zuraw QC, Sheng S, Jiang Y, Agarwal P, Zhou B, Zhuang Y, Shawi M, Karyekar CS, Deodhar A. Ritchlin CT, et al. Among authors: karyekar cs. RMD Open. 2021 Feb;7(1):e001457. doi: 10.1136/rmdopen-2020-001457. RMD Open. 2021. PMID: 33568556 Free PMC article. Clinical Trial.
Efficacy and safety of guselkumab in patients with active psoriatic arthritis who are inadequate responders to tumour necrosis factor inhibitors: results through one year of a phase IIIb, randomised, controlled study (COSMOS).
Coates LC, Gossec L, Theander E, Bergmans P, Neuhold M, Karyekar CS, Shawi M, Noël W, Schett G, McInnes IB. Coates LC, et al. Among authors: karyekar cs. Ann Rheum Dis. 2022 Mar;81(3):359-369. doi: 10.1136/annrheumdis-2021-220991. Epub 2021 Nov 24. Ann Rheum Dis. 2022. PMID: 34819273 Free PMC article. Clinical Trial.
Patterns of Medication Use in Systemic Lupus Erythematosus: A Multicenter Cohort Study.
Kandane-Rathnayake R, Louthrenoo W, Luo SF, Wu YJ, Chen YH, Golder V, Lateef A, Cho J, Navarra SV, Zamora L, Hamijoyo L, Sockalingam S, An Y, Li Z, Montes R, Oon S, Katsumata Y, Harigai M, Hao Y, Zhang Z, Chan M, Kikuchi J, Takeuchi T, Goldblatt F, O'Neill S, Bae SC, Lau CS, Hoi A, Karyekar CS, Nikpour M, Morand EF; Asia-Pacific Lupus Collaboration. Kandane-Rathnayake R, et al. Among authors: karyekar cs. Arthritis Care Res (Hoboken). 2021 Jul 1. doi: 10.1002/acr.24740. Online ahead of print. Arthritis Care Res (Hoboken). 2021. PMID: 34197023
Work absenteeism and disability associated with psoriasis and psoriatic arthritis in the USA-a retrospective study of claims data from 2009 TO 2020.
Orbai AM, Reddy SM, Dennis N, Villacorta R, Peterson S, Mesana L, Chakravarty SD, Lin I, Karyekar CS, Wang Y, Pacou M, Walsh J. Orbai AM, et al. Among authors: karyekar cs. Clin Rheumatol. 2021 Dec;40(12):4933-4942. doi: 10.1007/s10067-021-05839-9. Epub 2021 Jul 21. Clin Rheumatol. 2021. PMID: 34287723 Free PMC article.
Impact of guselkumab, an interleukin-23 p19 subunit inhibitor, on enthesitis and dactylitis in patients with moderate to severe psoriatic arthritis: results from a randomised, placebo-controlled, phase II study.
Mease PJ, Gladman DD, Deodhar A, McGonagle DG, Nash P, Boehncke WH, Gottlieb A, Xu XL, Xu S, Hsia EC, Karyekar CS, Helliwell PS. Mease PJ, et al. Among authors: karyekar cs. RMD Open. 2020 Jul;6(2):e001217. doi: 10.1136/rmdopen-2020-001217. RMD Open. 2020. PMID: 32665433 Free PMC article. Clinical Trial.
36 results